Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIORITY: Spironolactone for Prevention of Diabetic Nephropathy
NCT02040441Phase 3Completed
- Start
- Mar 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of spironolactone in diabetic nephropathy (DN). Started Mar 2014; status: completed.
02
Drugs
spironolactone
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02040441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040441.